I bought into MLA recently. I think it was overhyped and then oversold. The vendors of MediVet sold their business for $11m in an all scrip deal at 30c - that stake is now worth closer to $3m at current prices. That is a strong incentive!
The previous 4C showed strong positive cash flow, expectations for growth and costs under control. The blue sky story is in MediVet - the market there in the US is huge. The human healthcare division also looks to be starting to achieve some growth.
Will post more comments after the next update.
MLA Price at posting:
7.8¢ Sentiment: Buy Disclosure: Held
